protein

(redirected from accessory protein)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to protein

References in periodicals archive ?
Some of the possible outcomes of SSM include premature termination due to nonsense codon generation or altered protein due to frame-shifted mutation, loss or reduction of accessory proteins binding, loss or reduction of promoter's activity.3,24
HIV uses its accessory proteins such as the Vif that counteracts the apolipoprotein B mRNA-editing enzyme 3G (APOBEC3G), Vpr for SLX4 endonuclease complex, Vpu for bone marrow stromal antigen 2 (BST-2) or tetherin, and Vpx for SAM-domain HD-domain containing protein 1 (SAMHD1) [14-19].
It is possible that higher gene expression of other accessory proteins is required in order to achieve higher TEER levels early.
Lee et al., "Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule," Journal of Neuroscience, vol.
Considering the previously mentioned problems with the accuracy of ASPCR for allelic differentiation, we hypothesized that adding replication accessory proteins to our reactions would suppress potential false-positive results caused by high amounts of the wild-type allele.
The presence of this accessory protein was confirmed by SDS-PAGE as a band corresponding to 14 kDa (Fig.
But HIV has evolved a way to overcome restriction using an accessory protein called Vif (virion infectivity factor) to degrade the APOBEC proteins and allow the virus to spread.
The problems posed by HIV-1 latency in eradicating the virus during HAART, the role of the HIV accessory proteins e.g., NEF, VIF, VPR, VPU, VPX, etc., in viral pathogenesis, the mechanism underlying nuclear transport of HIV-I accessory protein Vpr, one of the significant agents in AIDS pathogenesis, have been emphasized in the section on basic research.
Cantargia develops antibody-based pharmaceuticals against the interleukin 1receptor accessory protein (IL1RAP).
CAN04 is in clinical development for cancer therapy and targets interleukin 1 receptor accessory protein, IL1RAP, positive single agent clinical data was recently presented at ESMO.
CAN04 is directed against interleukin-1 receptor accessory protein (IL1RAP) which is found on tumour cells from a wide range of cancer forms.
This poster presentation, with the title 'A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumours', was given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
This poster presentation, with the title 'A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumours', will be given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
The company uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukaemia.